Guardant Health Inc. GH shares fell in the extended session Monday after the cancer testing company announced a secondary offering of its stock. Guardant shares rose as much as 8% after hours, following a 2.5% rise to close the regular session at $30.80. The company said it plans to sell $250 million in shares with a 30-day option for an additional $37.5 million to cover overallotments. Underwriters include JP Morgan, Goldman Sachs, TD Cowen, and SVB Securities. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Read Full Story
Latest posts by Market Watch (see all)
- Mark Hulbert: Americans expect inflation to stay painfully high. That’s good news for stocks. - June 1, 2023
- Earnings Results: Lululemon stock jumps on sales forecast, as China’s reopening helps results - June 1, 2023
- Key Words: ‘Workers are not indentured servants,’ Supreme Court Justice Ketanji Brown Jackson says in dissent over union liability for strikes - June 1, 2023
